- Home
- LXEH vs CLNN Comparison
LXEH vs CLNN Comparison
Compare LXEH & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- CLNN
- Stock Information
- Founded
- LXEH 2001
- CLNN 2012
- Country
- LXEH China
- CLNN United States
- Employees
- LXEH N/A
- CLNN N/A
- Industry
- LXEH Other Consumer Services
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- CLNN Health Care
- Exchange
- LXEH Nasdaq
- CLNN Nasdaq
- Market Cap
- LXEH 55.2M
- CLNN 57.9M
- IPO Year
- LXEH 2020
- CLNN N/A
- Fundamental
- Price
- LXEH $2.43
- CLNN $6.17
- Analyst Decision
- LXEH
- CLNN Strong Buy
- Analyst Count
- LXEH 0
- CLNN 6
- Target Price
- LXEH N/A
- CLNN $32.67
- AVG Volume (30 Days)
- LXEH 4.3M
- CLNN 117.0K
- Earning Date
- LXEH 09-26-2025
- CLNN 11-12-2025
- Dividend Yield
- LXEH N/A
- CLNN N/A
- EPS Growth
- LXEH N/A
- CLNN N/A
- EPS
- LXEH N/A
- CLNN N/A
- Revenue
- LXEH $4,493,795.00
- CLNN $286,000.00
- Revenue This Year
- LXEH N/A
- CLNN N/A
- Revenue Next Year
- LXEH N/A
- CLNN $2,178.18
- P/E Ratio
- LXEH N/A
- CLNN N/A
- Revenue Growth
- LXEH N/A
- CLNN N/A
- 52 Week Low
- LXEH $1.12
- CLNN $2.28
- 52 Week High
- LXEH $50.08
- CLNN $7.10
- Technical
- Relative Strength Index (RSI)
- LXEH 63.64
- CLNN 59.58
- Support Level
- LXEH $2.26
- CLNN $5.77
- Resistance Level
- LXEH $2.69
- CLNN $6.54
- Average True Range (ATR)
- LXEH 0.22
- CLNN 0.57
- MACD
- LXEH 0.04
- CLNN -0.04
- Stochastic Oscillator
- LXEH 73.20
- CLNN 53.03
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.